SA PRO
Free Account
Intellia Therapeutics, Inc.NTLANASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 70% recommend buying.

Consensus Rating
Buy
30 analysts·High coverage
70%
Rating Distribution
Strong Buy
00%
Buy
2170%
Hold
827%
Sell
13%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 45% higher.

Bear Case
$7.00
-46%
Consensus
$19.00
+45%
Bull Case
$48.00
+268%
Price Range30 analysts
Low
Consensus
High
$7.00
$48.00
Current Target
Current Price
$13.06
Upside to Target
$5.94

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 28, 2026KeyBanc
Intellia Therapeutics (NTLA) PT Raised to $25 at H.C. Wainwright
Target:$25.00
+79.3%from $13.95
Jan 27, 2026Robert W. Baird
Intellia Therapeutics (NTLA) PT Raised to $7 at Baird
Target:$7.00
-51.4%from $14.39
Nov 11, 2025Evercore ISI
Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
Target:$8.00
-17.8%from $9.73
Nov 10, 2025Truist Financial
Intellia Therapeutics price target lowered to $14 from $25 at Truist
Target:$14.00
+41.3%from $9.91
Nov 7, 2025Oppenheimer
Intellia Therapeutics price target lowered to $27 from $33 at Oppenheimer
Target:$27.00
+173.6%from $9.87
Oct 30, 2025Wedbush
Intellia Therapeutics price target lowered to $9 from $14 at Wedbush
Target:$9.00
-27.9%from $12.49
Oct 30, 2025H.C. Wainwright
Intellia Therapeutics price target lowered to $18 from $25 at H.C. Wainwright
Target:$18.00
+37.2%from $13.12
Oct 30, 2025Robert W. Baird
Intellia Therapeutics (NTLA) PT Lowered to $9 at Baird
Target:$9.00
-31.4%from $13.12
Oct 28, 2025JMP Securities
Intellia Therapeutics price target lowered to $29 from $33 at Citizens JMP
Target:$29.00
+96.1%from $14.79
Oct 28, 2025Bernstein
Intellia Therapeutics downgraded to Market Perform from Outperform at Bernstein
Target:$14.50
-2.0%from $14.79
Oct 28, 2025Barclays
Intellia Therapeutics price target lowered to $24 from $26 at Barclays
Target:$24.00
+62.3%from $14.79
Oct 28, 2025Tudor Pickering
Bernstein SocGen Group Downgrades Intellia Therapeutics (NTLA) to Market Perform
Target:$14.50
-2.0%from $14.79
Oct 28, 2025RBC Capital
RBC Capital Downgrades Intellia Therapeutics (NTLA) to Sector Perform
Target:$14.00
-5.3%from $14.79
Oct 27, 2025Chardan Capital
Intellia Therapeutics price target lowered to $48 from $60 at Chardan
Target:$48.00
+87.5%from $25.60
Oct 27, 2025H.C. Wainwright
Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
Target:$25.00
-2.3%from $25.60
Oct 6, 2025JMP Securities
Intellia upgraded to Outperform from Market Perform at Citizens JMP
Target:$33.00
+65.3%from $19.96
Aug 13, 2025Guggenheim
Intellia Therapeutics (NTLA) PT Lowered to $14 at Guggenheim
Target:$14.00
+24.4%from $11.25
Feb 28, 2025Goldman Sachs
Intellia Therapeutics downgraded to Sell from Neutral at Goldman Sachs
Target:$9.00
-10.8%from $10.09
Feb 28, 2025Barclays
Intellia Therapeutics price target lowered to $26 from $55 at Barclays
Target:$26.00
+157.7%from $10.09
Nov 11, 2024Oppenheimer
Intellia Therapeutics (NTLA) PT Lowered to $60 at Oppenheimer
Target:$60.00
+249.7%from $17.16
Oct 24, 2024Robert W. Baird
Intellia Therapeutics (NTLA) PT Lowered to $18 at Baird
Target:$18.00
+13.6%from $15.85
Aug 9, 2024RBC Capital
Intellia Therapeutics (NTLA) PT Lowered to $54 at RBC Capital
Target:$54.00
+141.3%from $22.38
Jun 24, 2024Stifel Nicolaus
Stifel on Intellia Therapeutics (NTLA): 'Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach'
Target:$80.00
+217.2%from $25.22
Jun 24, 2024Robert W. Baird
Baird on Intellia Therapeutics (NTLA): 'we anticipate enthusiasm will wane'
Target:$24.00
-7.7%from $26.00
May 10, 2024BMO Capital
Intellia Therapeutics (NTLA) PT Raised to $70 at BMO Capital
Target:$70.00
+181.8%from $24.84

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance